


PHARMACEUTICAL 2018

Avalo Therapeutics Inc. Rank 59 of 342









PHARMACEUTICAL 2018



Avalo Therapeutics Inc. Rank 59 of 342



The relative strengths and weaknesses of Avalo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avalo Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 119% points. The greatest weakness of Avalo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 205%, being 159% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	10,991
Cost of Goods Sold	0
Intangible Assets	31,957
Liabilities, Current	11,406
Liabilities, Non-Current	24
Other Assets	131
Other Compr. Net Income	0
Other Expenses	3,576
Other Liabilities	3,834
Other Net Income	-54
Other Revenues	27,813
Property and Equipment	45
Research and Development	4,373
Selling, General and Administrative Expense	7,942

Output Variable	Value in 1000 USD
Assets	43,124
Liabilities	15,264
Expenses	15,890
Revenues	27,813
Stockholders Equity	27,860
Net Income	11,870
Comprehensive Net Income	11,870
Economic Capital Ratio	205%

